ARTICLE | Company News
Schering acquires Celera's CRA-028129
June 22, 2006 1:15 AM UTC
Schering (FSE:SCH; SHR) acquired CRA's cathepsin S inhibitor program, including CRA-028129, a small molecule that is in Phase I testing for psoriasis. The deal completes CRA's planned exit from small ...